Caladrius Biosciences Inc expected to post a loss of 10  cents a share - Earnings Preview

Lisata Therapeutics

04/05/2022 03:06

* Caladrius Biosciences Inc  CLBS.OQ   CLBS.O  is expected
to show
no change in quarterly revenue when it reports  results on May
5. 
    * ​Refinitiv's mean analyst estimate for Caladrius
Biosciences Inc
is for a loss of 10 cents per share. For the same quarter last
year, the company reported a loss of 19 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Caladrius
Biosciences Inc is $8​, above​ its last closing price of $0.55.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.13       -0.14      -0.11     Beat    24.1
 Sep. 30 2021  -0.13       -0.15      -0.12     Beat    20
 Jun. 30 2021  -0.14       -0.14      -0.10     Beat    31​
 Mar. 31 2021  -0.09       -0.08      -0.19     Missed  -123.5
 ​​Dec.        -0.27       -0.25      -0.28     Missed  -10.5
 31 2020                                                
 Sep. 30 2020  -0.24       -0.29      -0.29     Met     0​
 Jun. 30 2020  -0.40       -0.39      0.50      Beat    229
 Mar. 31 2020  -0.34       -0.29      -0.38     Missed  -31
 This summary was machine generated May 4 at 02:06 GMT.  All
figures in US dollars  unless otherwise stated